healthon tirzepatide Monthly Weight Loss Program ✨ Motivational Monday Spotlight ✨
Description
SURMOUNT-3 For the SURMOUNT-3 trial, patients who lost at least 5% of their body weight after a 12-week intensive lifestyle intervention lead-in period that included a low-calorie diet, exercise and weekly counseling sessions, were randomly assigned to receive either tirzepatide or placebo for 72 weeks to assess the efficacy and safety of the drug
Rapid heartbeat and dizziness
2024a, b)
Patients should seek immediate medical attention for severe abdominal pain (which may indicate pancreatitis), symptoms of gallbladder disease, signs of dehydration, allergic reactions, or any unusual neck mass or swelling
